![]() |
市场调查报告书
商品编码
1519433
2024-2032 年按产品、技术(聚合酶炼式反应、杂交、DNA 定序、微阵列、等温核酸扩增技术等)、应用、最终用户和地区分類的分子诊断市场报告Molecular Diagnostics Market Report by Product, Technology (Polymerase Chain Reactions, Hybridization, DNA Sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology, and Others), Application, End Users, and Region 2024-2032 |
2023年全球IMARC Group诊断市场规模达197亿美元。传染病和遗传性疾病的盛行率日益增加、聚合酶链反应(PCR)技术的进步、人口老化的加剧、早期疾病检测意识的提高以及政府的支持倡议是塑造市场轨蹟的因素。
主要市场驱动因素:分子诊断市场的扩张主要是由于慢性病和传染病的增加,这反过来又导致对准确诊断方法的需求不断增长。此外,基因组和个人化医学的不断进步也促进了分子诊断市场的成长。
主要市场趋势:实质趋势包括对 PCR 的需求,因为它准确、快速,以及由于新方法和诊断技术而导致试剂和试剂盒的增加。此外,向非侵入性早期诊断方法的发展也支持了这项需求。
地区趋势:北美由于拥有先进的医疗基础设施、更多的研发投资以及对个人化医疗的高度重视而处于世界领先地位。此外,亚太地区面临资源利用增加和健康相关知识和支出增加的快速发展。
竞争格局:不断为市场做出贡献的主要竞争公司有罗氏诊断、雅培实验室、凯杰、伯乐实验室、西门子医疗和赛默飞世尔科技等。这些企业大力投资新技术和合作伙伴关係,以保持分子诊断市场份额并占领新领域。
挑战与机会:障碍是分子诊断的复杂监管和财务状况。除了挑战之外,新兴市场不断增长的医疗保健需求以及不断进步的技术也为医疗保健提供者带来了新的机会,这些进步有望提供更好的诊断并扩大市场。
慢性病和传染病的盛行率不断上升
市场呈现出惊人的成长速度,这主要是由于急性和慢性疾病病例的增加。癌症、心臟病和感染等疾病发生率的增加凸显了分子诊断在快速、正确诊断疾病方面的重要作用。这一属性可以实现更好的患者治疗效果,并构成个别反应的个人化治疗计划,从而增加了市场上的分子诊断需求。随着世界各地健康状况日益复杂,对新型分子诊断设备的需求不断增加,这反过来又推动了市场的持续成长。根据卫生部的报告,2016年,非传染性疾病(NCD)占所有死亡病例的61%和致残病例的55%。
基因组学和个人化医疗的技术进步
该行业正在经历基因组学和个人化医疗的发展,这对于全球分子诊断市场趋势至关重要。 DNA 定序、基因表现和下一代 DNA 定序(如 RNA)的基因分析创新至关重要,它们改变了诊断方式,并允许识别特定的疾病标记和遗传倾向。个人化医疗的使用需要根据个人的基因图谱客製化治疗,这就产生了对复杂诊断技术的需求,这种技术能够准确地破解复杂的遗传讯息。先进技术和客製化治疗之间不断加强的合作正在扩大市场份额。
根据个人化医疗报道,2015年,美国总统欧巴马发起精准医疗倡议(PMI)。这项倡议使研究人员能够安全地存取大量基因组资料,从数千个基因组序列开始,可能扩展到一百万个基因组序列,以进行深入的科学研究。
人口老化加剧和对针对性诊断的需求
由于老年族群中神经退化性疾病和心血管问题等疾病的增加,对有效诊断方法的需求不断增加。分子诊断提供了早期检测健康状况的宝贵功能,从而为方便和改善结果的治疗提供了明确的途径。这一人群的成长趋势显着增加了对非侵入性和精确工具的需求,例如晶片实验室(LOA)技术,这表明越来越多的细分市场越来越倾向于适应这种新的健康要求。这种人口转变对分子诊断市场分析做出了重大贡献。
IMARC Group提供了全球分子诊断市场报告各细分市场主要趋势的分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、技术、应用和最终用户对市场进行了分类。
试剂和试剂盒
仪器
软体和服务
试剂和试剂盒主导市场
该报告根据产品提供了详细的市场细分和分析。这包括试剂和试剂盒、仪器以及软体和服务。根据该报告,试剂和试剂盒占最大部分。
由于分子诊断扩展到各个专业医疗领域,市场正在经历显着成长,特别是在试剂和试剂盒领域。研究和新颖发明的新范式产生了新颖的测定和测试方法,需要适当的试剂和试剂盒才能可行。慢性病数量的不断增加使得对快速、可靠的诊断工具的需求变得更加重要,从而推动了这种成长。大公司与研究机构的参与也对新试剂和试剂盒的开发产生影响,因此在增加分子诊断市场收入方面发挥重要作用。
聚合酶炼式反应 (PCR)
杂交
DNA定序
微阵列
等温核酸扩增技术(INAAT)
其他的
聚合酶炼式反应 (PCR) 主导市场
该报告基于该技术对市场进行了详细的细分和分析。这包括聚合酶炼式反应 (PCR)、杂交、DNA 定序、微阵列、等温核酸扩增技术 (INAAT) 等。根据该报告,聚合酶链反应(PCR)代表了最大的部分。
PCR 领域主导分子诊断市场前景。 PCR 技术改进的出现,包括 qPCR 和 dPCR 的设计和构建,推动了扩增的生化过程,从而提高了灵敏度、准确性和速度。 PCR 的进步使其成为分子诊断中不可或缺的工具。可用于个人化医疗和标靶治疗的基因图谱的精确分析现在对于这些治疗至关重要。此外,护理点诊断的进步和 PCR 平台在医疗保健专业人员和患者中的引入使分子检测变得更加容易,这扩大了其在医疗保健环境中的整合。
传染病诊断
肿瘤学
基因检测
血液筛检
其他的
传染病诊断主导市场
该报告根据应用程式提供了详细的市场细分和分析。这包括传染病诊断、肿瘤学、基因检测、血液筛检等。根据该报告,传染病诊断占最大部分。
分子诊断市场概述解释说,市场动态与传染病的快速传播一致,包括病毒、细菌和真菌感染。疾病的迅速传播,特别是那些有可能使世界陷入大流行的疾病,迫切需要早期发现机制和使用可行的遏制策略。分子生物学和免疫分析技术在诊断领域的出现,透过提高病原体检测和抗药性分型的准确性和速度,彻底改变了这一领域。这项突破为分子诊断创造了一个充满希望的市场,并显示预防性健康和监测计画的强劲成长趋势。这些措施在医疗参与和阻止感染传播方面发挥着重要作用。
医院
实验室
其他的
该报告根据最终用户对市场进行了详细的细分和分析。这包括医院、实验室等。
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美表现出明显的主导地位,占据最大的分子诊断市场份额
市场研究报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告称,北美是分子诊断最大的区域市场。
根据分子诊断市场预测期,由于持久研发创新的强大文化,北美市场正在成长。随着癌症、心血管疾病和糖尿病等慢性疾病发生率的增加,需要快速、可靠的检测方法。医疗保健专业人员和患者对个人化医疗理解程度的提高以及其他因素正在推动市场成长。政府对医疗保健现代化援助的发展和分子诊断技术的建立是业务成长的主要经济驱动力。此外,DTC基因检测也是提高消费者互动水平并支持分子诊断市场近期机会的重要组成部分。
The global molecular diagnostics market size reached US$ 19.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032. The increasing prevalence of infectious diseases and genetic disorders, technological advancements in polymerase chain reaction (PCR), growing aging population, surging awareness of early disease detection, and supportive government initiatives are factors shaping the market's trajectory.
Major Market Drivers: The market for molecular diagnostics is expanding primarily due to rise in chronic and infectious illnesses which in turn is leading to growing demand for accurate diagnostics methods. In addition, the continual advancements in genomic and personalized medicine are contributing to the molecular diagnostics market growth.
Key Market Trends: Substantial trends include the demand for PCR as it is accurate and fast and the increase in reagents and kits due to the new methodologies and diagnostic technologies. Besides, the movement towards non-invasive, early diagnosis approaches is also supporting the demand.
Geographical Trends: North America is the leader in the world, due to the presence of advanced medical infrastructure, more investments in R&D and a great emphasis on personalized medicine. In addition, Asia-Pacific faces a fast development through increasing resource usage and more health-related knowledge and spendings.
Competitive Landscape: The key competitive companies that are constantly contributing to the market are Roche Diagnostics, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, Siemens Healthineers, and Thermo Fisher Scientific and others. These enterprises invest heavily in the new technologies and partnerships to maintain the molecular diagnostics market share and occupy new territories.
Challenges and Opportunities: The barriers are regulatory intricacies and finances of the molecular diagnostics. Along with the challenges, new opportunities emerge for healthcare providers from the growing healthcare needs in the emerging markets and from the constant technological advances which promise better diagnostics and expand the market.
Increasing prevalence of chronic and infectious diseases
The market is exhibiting an outstanding growth rate which is mainly due to the increasing cases of acute and chronic illnesses. This increase in disease occurrence, including cancer, heart diseases, and infection focuses on the significant role of the molecular diagnostics in giving fast and proper diagnosis of the disease. This attribute enables the better patient outcomes and also constitutes individual response personalized treatment plans, which increases the molecular diagnostics demand in the market. Along with the expanding complexities of health conditions all over the world, the demand for newfangled molecular diagnostic equipment is rising, which in turn perpetuates the market growth. According to a report by the ministry of health, in 2016, non-communicable diseases (NCDs) accounted for 61% of all mortalities and 55% of disability cases.
Technological advancements in genomics and personalized medicine
The sector is experiencing developments in genomics and personalized medicine that are crucial for the global molecular diagnostics market trends. Genetic profiling innovations for DNA sequencing, gene expression, and next-generation DNA sequencing such as RNA are essential and changing the ways of diagnosis and allowing the identification of specific disease markers and genetic predispositions. The utilization of personalized medicine, which entails to tailoring treatment based on the individual's genetic profile, is creating a need for sophisticated diagnostic technologies, that is able to decipher complex genetic information accurately. The rising cooperation between sophisticated technologies and tailored treatments is expanding the market share.
According to the personalized medicine report, in 2015, U.S. President Barack Obama launched the precision medicine initiative (PMI). This initiative offers researchers secure access to an extensive array of genomic data, starting with thousands and potentially expanding to one million genome sequences, for in-depth scientific research.
Rising aging population and demand for targeted diagnostics
The demand for efficient diagnostic method is rising due to rising illnesses, such as neurodegenerative disorders and cardiovascular problems in geriatric populations. Molecular diagnostics offer a valuable functionality of early detection of health conditions, thus providing a clear path for treatment at convenient and improved outcomes. The growing trend of this demographic is significantly increasing demand for non-invasive and accurate tools such as lab-on-a-chip (LOA) technology which is indicative of an increasing market segment's inclination to adapt to this new health requirement. This population shift is a significant contributing to the molecular diagnostics market analysis.
IMARC Group provides an analysis of the key trends in each segment of the global molecular diagnostics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, technology, application, and end users.
Reagents and Kits
Instruments
Software and Services
Reagents and kits dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes reagents and kits, instruments, and software and services. According to the report, reagents and kits represented the largest segment.
The market is experiencing a significant increase, particularly in the reagents and kits segment, due to the expansion of molecular diagnostics reach into various medical areas of specialization. Fresh paradigms in research and novel inventions generate novel assays and testing methods that require the appropriate reagents and kits to be feasible. The growing number of chronic diseases make the need for fast and dependable diagnostic tools more crucial, driving the increase. Involvement of the major companies with research institutions also has an impact on the development of new reagents and kits, and hence plays a significant part in increasing the molecular diagnostics market revenue.
Polymerase Chain Reactions (PCR)
Hybridization
DNA Sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
Polymerase chain reactions (PCR) dominate the market
The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reactions (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others. According to the report, polymerase chain reactions (PCR) represented the largest segment.
The PCR segment is dominating the molecular diagnostics market outlook. The advent of PCR technology refinements, including the designing and constructing of qPCR and dPCR, propel the amplification's biochemical process, thereby improves the sensitivity, accuracy, and speed. Such advancement of PCR has made it an indispensable instrument in molecular diagnostics. Precise analysis of genetic profiles which can be used in personalized medicine and targeted therapies is now essential to these treatments. Besides, the point-of-care diagnostics advancement and PCR platform introduction into both of the healthcare professionals and patients make molecular testing more available this leads broaden its integration among healthcare environments.
Infectious Diseases Diagnostics
Oncology
Genetic Testing
Blood Screening
Others
Infectious diseases diagnostics dominate the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes infectious diseases diagnostics, oncology, genetic testing, blood screening, and others. According to the report, infectious diseases diagnostics represented the largest segment.
The molecular diagnostics market overview explains that the market dynamics are in line with rapid spread of infectious diseases, encompassing viral, bacterial, and fungal infections. The rapid spread of diseases, especially those which have the potential to plunge the world into pandemics, has caused an urgent need for early detection mechanism and the use of viable containment strategies. The advent of molecular biology and immunoassay technologies in diagnostics revolutionized this landscape by enhancing the accuracy and speed of pathogen detection and typing for their resistances. This breakthrough has led to the creation of a promising market for molecular diagnostics and indicates a strong trend of the growth of preventive health and surveillance projects. These measures play an important role in the medical involvement and stopping the spread of infections.
Hospitals
Laboratories
Others
The report has provided a detailed breakup and analysis of the market based on end users. This includes hospitals, laboratories, and others.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest molecular diagnostics market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for molecular diagnostics.
North America market is growing due to the strong culture of perpetual research and development innovation, as per the molecular diagnostics market forecast period. With the increase in the development of chronic diseases, such as cancer, cardiovascular diseases and diabetes, the rapid and reliable detection methods are required. The increased level of personalized medicine understanding in healthcare professionals and patients alongside other factors is propelling the market growth. Development of government aid in the healthcare modernization and the establishment of molecular diagnostics techniques are the major economies drivers in the business growth. Furthermore, DTC genetic testing is also a significant part which improves the level of consumer interaction and supports the molecular diagnostics market recent opportunities.
Abbott Laboratories
Agilent Technologies Inc.
Becton Dickinson and Company
Biomerieux SA
Danaher Corporation
Diasorin Molecular LLC (DiaSorin)
F. Hoffmann-La Roche AG (Roche Holding AG)
Hologic Inc.
Illumina Inc.
Myriad Genetics Inc.
Qiagen
Quidel Corporation
Thermo Fisher Scientific
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Key molecular diagnostics companies are getting involved in the latest trends in the industry, such as Abbott Laboratories and Agilent Technologies Inc. Leading bio-pharmaceutical firms drive the improvements in diagnostic technology through introduction of newer, more precise, and better tested products. Besides, global giants are continuing to grow their presence across various regions with acquisitions, mergers, and different partnerships in order to increase their market share and facilitating the access to new markets. These strategic moves expand their product lines and improve the quality of their activity, catering to the all-time demand for a customized and point-of-care diagnoses. Molecular diagnostics recent developments include a merger of AI and machine learning technologies that better facilitate data analysis and enhance the accuracy of diagnostics.
In May 2023, Becton Dickinson and Company announced to invest US$ 80 million in the construction of its third plant in Ciudad Juarez.
In January 2023, Agilent Technologies and Akoya Biosciences collaborated to develop multiplex-immunohistochemistry diagnostic products for tissue analysis. The companies also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.
In April 2023, Abbott announced the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.